Follistatin 315
Activin-Binding Protein, FSH-Suppressing Protein, FST-315, FS-315
Completed
NA
INTERVENTIONAL
NCT03464500
AMAZ-02 Effect on Exercise ToLerance in Healthy, Overweight Middle Aged Subjects (ATLAS Trial)
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
This is a Phase 2 randomized, double-blind, placebo-controlled study enrolling 90 healthy, overweight, middle aged subjects (30 placebo, 30 low dose and 30 high dose AMAZ-02 intervention), 40-65 years of age, who are otherwise healthy. AMAZ-02, a food derived ingredient, will be given as a daily oral dose for 4 months.
Interventions
Name:
Mitopure 500mg
Type:
DIETARY_SUPPLEMENT
Description:
Mitopure containing softgels
Name:
Mitopure 1000mg
Type:
DIETARY_SUPPLEMENT
Description:
Mitopure containing softgels
Name:
Placebo
Type:
DIETARY_SUPPLEMENT
Description:
Placebo containing softgels
Primary Outcomes
Measure:
Change in exercise tolerance as assessed by power output on the cycle ergometer from baseline to day 120 between AMAZ-02 groups and placebo
TimeFrame:
4 months
Description:
Trial Information
NCT ID
NCT03464500
Status
Completed
Study Type
INTERVENTIONAL
Phases
NA
Sponsor
Amazentis SA
Last Updated
December 15, 2025